Elutia (NASDAQ:ELUT) is a commercial-stage company focused on developing and selling drug-eluting biomatrix products in the United States. These products combine biocompatible materials with medications to improve how medical devices interact with the body. Elutia's target markets include neurostimulation, wound care, and breast reconstruction. By enhancing compatibility, they aim to reduce complications and improve patient outcomes. The company is still growing, and anticipates a regulatory decision for its CanGarooRM product in the first half of 2024.